Previous Close | 0.286 |
1-Year Change | -85.26% |
6-Months Change | -68.33% |
3-Months Change | 15.79% |
Moving Avg (50d) | 0.336 |
Moving Avg (200d) | 0.6143 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 15.6M |
Beta (3-Years) | 1.24 |
Revenue Growth (ttm) | -46.17% |
Net Profit Margin (ttm) | -548.95% |
Return On Assets (ttm) | -101.02% |
EPS (ttm) | -2.15 |
PE Ratio (ttm) | -0.13 |
Dividend Yield | % |
Asset Description: | Cara Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.292 | 0.3 | 0.306 | 0.315 | 0.329 | 0.343 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |